Stock taking stock of the latest advances in innovative treatments for lung cancer

90% of the disease control rate! One of the highlights of today's ASCO Annual Meeting of thefirst KRAS G12C inhibitors was undoubtedly the KRAS G12C inhibitor AMG 510 brought by AmgenThis is also the first KRAS G12C inhibitor to enter the clinical phase after decades of research into the RAS geneIn Phase 1 clinical trials, its anti-tumor activity is full of potentialthe study recruited 35 patients with the KRAS G12C mutation who had different types of cancer and had previously received two or more other treatmentsOf the 10 assessable non-small cell lung cancer patients, 5 showed partial remission and four were in stable conditionAs a result, the current disease control rate is 90%! Amin's press release noted that after the data cut-off, one patient's condition improved further, from partial to complete relief!the molecular structure of the AMG 510 (Photo: C.EN)the main endpoint of this study is safetyNo toxicity of the limit dose has been observed at the dose level stophonatedthe results are encouragingDrDavid MReese, executive vice president of research and development at Amgen, points out that KRAS is one of the first cancer-causing genes to be discovered in humans, but it has long been considered "ineffective" because of its protein's lack of "binding pockets" of traditional small molecule drugsBy decoding KRAS, the researchers found a hidden "groove" on the surface of its protein, which also made it possible to target KRAS" is able to lock the mutant KRAS protein in a state of inactivation by irreversibly binding to no12 cysteine in the mutated KRAS protein Because of its highly selective approach to KRAS G12C, we believe the AMG 510 offers high therapeutic potential as a single drug and in combination with other targeted and immunotherapy therapies Dr Reese added 60% overall relief! RET Inhibitors are due to go on the market next year
Blueprint Medicines, a company focused on precision therapies Today, it announces the latest developments in THE RET inhibitor BLU-667: in patients with RET fusion mutations, its overall remission rate is 60%! in a clinical trial called ARROW, researchers recruited nearly 200 cancer patients with RET mutations, including 120 non-small cell lung cancer patients with RET fusion mutations At the data cut-off, a total of 48 lung cancer patients were assessed The study showed that 90 percent of the 35 patients who had previously undergone platinum chemotherapy had their tumor size reduced in radiology imagery The overall remission rate for these patients was 60%, including 1 full remission and 20 partial remissions In addition, 78 percent of the nine patients with measurable brain metastasis experienced a reduction in brain metastasis The molecular structure of BLU-667 (Photo: Cancer Discovery) researchers point out that targeted therapies have dramatically changed the treatment of cancer, but no new drugs have been approved for targeted RETs The BLU-667 showed a high mitigation rate and supported the new drug's application in the first quarter of next year It has now been certified as a breakthrough therapy by the FDA updated data from more than one MET inhibitor, the mitigation rate was encouraging
with met-mutations accounting for about 3-5% of the total in non-small cell lung cancer For MET mutations, we do not currently have approved targeted therapies, so the prognosis for these patients is not optimistic the results of a number of MET inhibitor studies were published at today's ANNUAL MEETING of ASCO The first drug was capmatinib, originally discovered by Incyte, and licensed to Novartis in 2009 In a clinical trial called GEOMETRY mono-1, researchers recruited 97 patients with advanced or metastatic non-small cell lung cancer with met14 exon jump mutations 's molecular structure (Photo: PubChem-NIH) results show that Capmatinib has potential effects regardless of whether a patient has previously been treated The overall remission rates of capmatinib were 68% and 41% respectively among first-treatment and treated patients The median efficacy duration was 11.14 months and 9.72 months in the two groups, respectively based on these results, Novartis plans to submit its ipo application to the FDA this year Previously, this MET inhibitor has been certified as a breakthrough therapy granted by the FDA on the same day , Germany's Merck KGaA also released its latest research results In phase 2 clinical trials called VISION, the efficacy of 73 patients was evaluated These patients also have non-small cell lung cancer and are confirmed to have met14 exon jump mutations through a liquid biopsy or tissue biopsy Tepotinib's molecular structure (Photo: PubChem-NIH) the overall remission rate of the Independent Evaluation Committee (IRC) was 50.0 percent for patients confirmed by liquid biopsies, compared with 55.3 percent for the researchers For patients confirmed by tissue biopsies, the two figures were 45.1% and 54.9%, respectively In the median disease control time, the IRC gave 12.4 months and 15.7 months, respectively, for patients whose liquid biopsies and tissue biopsies confirmed For both groups of patients, the researchers gave 17.1 months and 14.3 months, respectively the researchers noted that the results were consistent with previous efficacy shown by tepotinib The inclusion of liquid biopsies will also help patients with accurate screening the next few days, the drug Ming Kang de Wechat team will continue to send you readers ASCO updates and summary of the resumed, please pay attention! References: 1 s Am Announcegens First Clinical Data Evaluating Novel Investigation al KRASG12C AMG 510 At ASCO 2019, Retrieved 3, 2019, from https:// 2) Blueprint S' Blueprint S' Highly Selective RET BL-667 ShowAnt Ant-Instagram In Patients with RET-Altered Cancers in Updated ARROW Data Trial Presented at ASCO 2019, Retrieved June 3, 2019, from http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-highly-selective-ret-inhibitor-blu-667-shows ClinicalLy Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated With Age 3, June 3, 2019, from https:// Tepotinib Brisbane Clinical End A Clinical Response In Patients with Advanced NSCLC with METex14 Skipping Progress, Retrieved June 3, 2019, https:// original title: ASCO - Treatment of Lung Cancer, these heavyweight sprogressyou must know!